|
TWST: We would like to begin with a brief historical sketch of Cambridge
Health and a picture of the things you are doing now.
Mr. Chazanovitz: Cambridge Heart has been around for a while. It was
founded originally in 1990 and had a successful IPO with Goldman Sachs
and Bear Sterns in 1996. We have been continuously engaged, since that
point in time, in the research and development of products for the non-
invasive diagnosis of cardiac disease. We've been concentrating on
identifying individuals who may be at risk for sudden cardiac death. The
product, which is called the HearTwave, is one that uses the power of
the computer as its base product with an algorithm that helps to look in
the patient's electrocardiogram for a signal, which may suggest to us
that they are at risk of dying suddenly from an electrical abnormality
or bad beat rhythm. TWST: How do you determine who should be tested in the first place?
Mr. Chazanovitz: Some people look at our test and suggest that it should
be done routinely as a part of any individual's physical. Somewhere down
the line that might be the case. However, right now, the individuals who
we're looking to test are those who have some structural heart problem,
meaning somebody who has had a previous heart attack or somebody who may
be in heart failure. Those individuals are clearly recognized as being
at high risk of sudden cardiac death, and we can help determine which of
those people really are at high risk of sudden cardiac death and
therefore might benefit from having an implantable defibrillator put in
them, and which of them are really at low risk of sudden death and can
be appropriately treated with standard cardiac medications.
Tickers included in this excerpt:
For more information call (212) 952 7433. The
Wall Street Transcript does not endorse any of the comments made by interviewees, and does
not make stock recommendations.
|
|
